Phaseline

Companies › Xeno Holdings (US), LLC dba ChoironeX

Xeno Holdings (US), LLC dba ChoironeX: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ChoironeX GalKO Porcine Thymokidney
Genetically modified porcine thymokidney with knockout of alpha-gal epitope (GalKO) for xe
GGTA1Phase 1End Stage Renal DiseaseJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07696962ChoironeX GalKO Porcine ThymokidneyPhase 1End Stage Renal DiseaseGenitourinaryJun 2028

Targets

GGTA1 (1)

Companies with the same targets

United Therapeutics Prescient Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.